No effect of cysteine on the pharmacokinetics of intravenous azosemide in rats with protein-calorie malnutrition by pretreatment with 3-methylcholanthrene.
The effects of cysteine on the pharmacokinetics of azosemide were investigated after intravenous administration of drug, 10 mg/kg, to male Sprague-Dawley rats pretreated with 3-methylcholanthrene fed on 23% protein diet (control rats) and 5% protein diet without (rats with protein-calorie malnutrition, PCM) or with (rats with PCMC) oral cysteine (250 mg/kg, twice daily starting from the fourth week) for 4 weeks. After intravenous administration to rats with PCM, the metabolites of azosemide excreted in urine and recovered from gastrointestinal tract decreased significantly than those in control rats, however, the plasma concentrations, total area under plasma concentration-time curve from time zero to time infinity (AUC) and time-averaged total body clearance (CL) were not significantly different between two groups of rats. It was reported that after intravenous administration of azosemide, 10 mg/kg, to rats with PCMC without pretreatment 3-methylcholanthrene, some pharmacokinetic parameters restored fully or more than the level of control rats; the time-averaged nonrenal clearance and apparent volume of distribution at steady state were comparable to those in control rats, but the terminal half-life and mean residence time were significantly shorter, AUC was significantly smaller, and time-averaged renal clearance and CL were significantly faster than those in control rats. However, the above mentioned effects of cysteine on the pharmacokinetic parameters of azosemide in rats with PCM were not observed with pretreatment with 3-methylcholanthrene.
Kim
Y G
YG
College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, San 56-1, Shinlim-Dong, Kwanak-Gu, Seoul 151-742, South Korea.
Cho
M K
MK
Kwon
J W
JW
Kim
S H
SH
Kim
S G
SG
Lee
M G
MG
D000818:Animals; D019540:Area Under Curve; D001835:Body Weight / Q000187:drug effects; D003545:Cysteine / Q000494:pharmacology*; D004232:Diuretics / Q000097:blood / Q000493:pharmacokinetics*; D006207:Half-Life; D007262:Infusions, Intravenous; D008297:Male; D008657:Metabolic Clearance Rate; D008748:Methylcholanthrene / Q000633:toxicity; D011502:Protein-Energy Malnutrition / Q000139:chemically induced / Q000378:metabolism*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013424:Sulfanilamides / Q000097:blood / Q000493:pharmacokinetics*; D014018:Tissue Distribution; D013777:Tetrazoles; D013876:Thiophenes; D000096926:Benzenesulfonamides
D003545:Cysteine; D004232:Diuretics; D008748:Methylcholanthrene; D013424:Sulfanilamides; C018222:azosemide; D013777:Tetrazoles; D013876:Thiophenes; D000096926:Benzenesulfonamides